These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 21533297)
1. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. Silverberg JI; Silverberg NB J Drugs Dermatol; 2011 May; 10(5):507-10. PubMed ID: 21533297 [TBL] [Abstract][Full Text] [Related]
2. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898 [TBL] [Abstract][Full Text] [Related]
3. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355 [TBL] [Abstract][Full Text] [Related]
4. Topical tacrolimus for treatment of childhood vitiligo in Asians. Kanwar AJ; Dogra S; Parsad D Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845 [TBL] [Abstract][Full Text] [Related]
6. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Tanghetti EA Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Travis LB; Weinberg JM; Silverberg NB Arch Dermatol; 2003 May; 139(5):571-4; discussion 573. PubMed ID: 12756092 [No Abstract] [Full Text] [Related]
9. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094 [TBL] [Abstract][Full Text] [Related]
10. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Taher ZA; Lauzon G; Maguiness S; Dytoc MT Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859 [TBL] [Abstract][Full Text] [Related]
11. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562 [TBL] [Abstract][Full Text] [Related]
12. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. Fai D; Cassano N; Vena GA J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000 [TBL] [Abstract][Full Text] [Related]
13. Topical immunomodulators are effective for treatment of vitiligo. Choi CW; Chang SE; Bak H; Choi JH; Park HS; Huh CH; Kim CW; Kim SE; Mun SK; Kim BJ; Kim MN J Dermatol; 2008 Aug; 35(8):503-7. PubMed ID: 18789070 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. Udompataikul M; Boonsupthip P; Siriwattanagate R J Dermatol; 2011 Jun; 38(6):536-40. PubMed ID: 21352308 [TBL] [Abstract][Full Text] [Related]
15. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545 [TBL] [Abstract][Full Text] [Related]
16. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. Nordal EJ; Guleng GE; Rönnevig JR J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589 [TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214 [TBL] [Abstract][Full Text] [Related]
18. Topical tacrolimus for repigmentation of vitiligo. Grimes PE; Soriano T; Dytoc MT J Am Acad Dermatol; 2002 Nov; 47(5):789-91. PubMed ID: 12399778 [TBL] [Abstract][Full Text] [Related]
19. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Majid I Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696 [TBL] [Abstract][Full Text] [Related]
20. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo. Sehgal VN J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1218-9. PubMed ID: 19192018 [No Abstract] [Full Text] [Related] [Next] [New Search]